Ocular Therapeutix, Inc (OCUL) income statement
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$5.94−0.08 (-1.33%)
Close on Nov 18, 2026Market cap $1.30BP/E –Yield –
Ocular Therapeutix, Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 87.1%
- Operating margin
- -603.0%
- Net margin
- -579.1%
- Return on equity, FY2025
- -54.9%
Financial strength
- Current ratio
- 13.11
- Debt to equity
- 0.14
- Debt to assets
- 10.8%
- Cash to current liabilities
- 1217.4%
Valuation
- P/E ratio
- –
- Price to sales
- 25.06
- Price to book
- 2.51
- Dividend yield
- –
See a number that looks wrong?